公开(公告)号：US11338016B2

公开(公告)日：2022-05-24

申请号：US16878809

申请日：2020-05-20

Applicant: Howard University

Inventor： Yousef Tizabi

IPC: A61K38/16 ,  A61K9/00

Abstract: C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) provides therapeutic effects in motor impairments associated with Parkinson disease (PD), and provides long lasting antidepressant effects, thus useful in treating and mitigating depression, particularly PD-depression co-morbid condition. A method for treating or mitigating depression, including administrating an effective amount of C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) to a subject in need thereof. A method for treating or mitigating motor impairments associated with Parkinson's disease (PD), including administrating an effective amount of C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) to a subject in need thereof.

公开(公告)号：US12168035B2

公开(公告)日：2024-12-17

申请号：US17729502

申请日：2022-04-26

Applicant: HOWARD UNIVERSITY

Inventor： Yousef Tizabi

IPC: A61K38/16 ,  A61K9/00

Abstract: C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) provides therapeutic effects in motor impairments associated with Parkinson disease (PD), and provides long lasting antidepressant effects, thus useful in treating and mitigating depression, particularly PD-depression co-morbid condition. A method for treating or mitigating depression, including administrating an effective amount of C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) to a subject in need thereof. A method for treating or mitigating motor impairments associated with Parkinson's disease (PD), including administrating an effective amount of C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) to a subject in need thereof.

公开(公告)号：US11541004B2

公开(公告)日：2023-01-03

申请号：US16897780

申请日：2020-06-10

Applicant: HOWARD UNIVERSITY

Inventor： Yousef Tizabi ,  Robert L. Copeland

IPC: A61K31/465 ,  A61K9/00 ,  A61P25/16

Abstract: A method for treating or mitigating Parkinson's disease (PD) symptoms or progression, including administering an effective amount of nicotine to a subject in need thereof, via inhalation using a nicotine inhaler or via nasal spray using a nicotine nasal spray. Significant dose-dependent improvement of all symptoms by nicotine inhaler or nicotine nasal spray is expected. A novel treatment in PD is thus provided.